Drugs that contain Olodaterol Hydrochloride

1. Drug name - STRIVERDI RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(1 year, 1 month from now)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(1 year, 2 months from now)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(2 years from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(4 years from now)

CN1713914A BOEHRINGER INGELHEIM New Medicine For Treating Chronic Obstructive Pulmonary Disease
Aug, 2010

(12 years ago)

CN101133039A BOEHRINGER INGELHEIM Novel Enantiomer Pure Beta-Agonists And Preparation Method And Use Thereof In Medicine Form
Mar, 2013

(9 years ago)

CN102827097B BOEHRINGER INGELHEIM Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form
May, 2025

(2 years from now)

CN102827097A BOEHRINGER INGELHEIM Novel Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form
May, 2025

(2 years from now)

IN200501999P1 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Disease
Nov, 2023

(1 year, 1 month from now)

IN225518B BOEHRINGER INGELHEIM Novel Substitued [1,1-Dimethyl-Ethyl-Amino)-I-Hydroxy-Ethyl]-6-Hydroxy-4H-Benzo[1,4]Oxazin-3-Ones) Compounds
Nov, 2023

(1 year, 1 month from now)

EP1562603B3 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases
Jul, 2020

(2 years ago)

EP1562603B1 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases
Jul, 2020

(2 years ago)

EP1562603A2 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases
Jul, 2020

(2 years ago)

EP1789405B1 BOEHRINGER INGELHEIM Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug
May, 2025

(2 years from now)

EP1789405A1 BOEHRINGER INGELHEIM Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease Nov, 2023

(1 year, 1 month from now)

US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease Nov, 2023

(1 year, 1 month from now)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties Aug, 2024

(1 year, 10 months from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments May, 2025

(2 years from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function May, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device Oct, 2026

(4 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism Oct, 2030

(8 years from now)

Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.0025MG BASE/INH SPRAY, METERED;INHALATION Prescription

availability in other generic markets.

Click on the highlighted region to filter.